Cargando…

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

BACKGROUND: Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients. METHODS: In this cross-sectional study we measured soluble amyloid precursor proteins alph...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisslén, Magnus, Krut, Jan, Andreasson, Ulf, Blennow, Kaj, Cinque, Paola, Brew, Bruce J, Spudich, Serena, Hagberg, Lars, Rosengren, Lars, Price, Richard W, Zetterberg, Henrik
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807422/
https://www.ncbi.nlm.nih.gov/pubmed/20028512
http://dx.doi.org/10.1186/1471-2377-9-63
_version_ 1782176399033892864
author Gisslén, Magnus
Krut, Jan
Andreasson, Ulf
Blennow, Kaj
Cinque, Paola
Brew, Bruce J
Spudich, Serena
Hagberg, Lars
Rosengren, Lars
Price, Richard W
Zetterberg, Henrik
author_facet Gisslén, Magnus
Krut, Jan
Andreasson, Ulf
Blennow, Kaj
Cinque, Paola
Brew, Bruce J
Spudich, Serena
Hagberg, Lars
Rosengren, Lars
Price, Richard W
Zetterberg, Henrik
author_sort Gisslén, Magnus
collection PubMed
description BACKGROUND: Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients. METHODS: In this cross-sectional study we measured soluble amyloid precursor proteins alpha and beta (sAPPα and sAPPβ), amyloid beta fragment 1-42 (Aβ(1-42)), and total and hyperphosphorylated tau (t-tau and p-tau) in CSF of 86 HIV-infected (HIV+) subjects, including 21 with AIDS dementia complex (ADC), 25 with central nervous system (CNS) opportunistic infections and 40 without neurological symptoms and signs. We also measured these CSF biomarkers in 64 uninfected (HIV-) subjects, including 21 with Alzheimer's disease, and both younger and older controls without neurological disease. RESULTS: CSF sAPPα and sAPPβ concentrations were highly correlated and reduced in patients with ADC and opportunistic infections compared to the other groups. The opportunistic infection group but not the ADC patients had lower CSF Aβ(1-42 )in comparison to the other HIV+ subjects. CSF t-tau levels were high in some ADC patients, but did not differ significantly from the HIV+ neuroasymptomatic group, while CSF p-tau was not increased in any of the HIV+ groups. Together, CSF amyloid and tau markers segregated the ADC patients from both HIV+ and HIV- neuroasymptomatics and from Alzheimer's disease patients, but not from those with opportunistic infections. CONCLUSIONS: Parallel reductions of CSF sAPPα and sAPPβ in ADC and CNS opportunistic infections suggest an effect of CNS immune activation or inflammation on neuronal amyloid synthesis or processing. Elevation of CSF t-tau in some ADC and CNS infection patients without concomitant increase in p-tau indicates neural injury without preferential accumulation of hyperphosphorylated tau as found in Alzheimer's disease. These biomarker changes define pathogenetic pathways to brain injury in ADC that differ from those of Alzheimer's disease.
format Text
id pubmed-2807422
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28074222010-01-16 Amyloid and tau cerebrospinal fluid biomarkers in HIV infection Gisslén, Magnus Krut, Jan Andreasson, Ulf Blennow, Kaj Cinque, Paola Brew, Bruce J Spudich, Serena Hagberg, Lars Rosengren, Lars Price, Richard W Zetterberg, Henrik BMC Neurol Research article BACKGROUND: Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients. METHODS: In this cross-sectional study we measured soluble amyloid precursor proteins alpha and beta (sAPPα and sAPPβ), amyloid beta fragment 1-42 (Aβ(1-42)), and total and hyperphosphorylated tau (t-tau and p-tau) in CSF of 86 HIV-infected (HIV+) subjects, including 21 with AIDS dementia complex (ADC), 25 with central nervous system (CNS) opportunistic infections and 40 without neurological symptoms and signs. We also measured these CSF biomarkers in 64 uninfected (HIV-) subjects, including 21 with Alzheimer's disease, and both younger and older controls without neurological disease. RESULTS: CSF sAPPα and sAPPβ concentrations were highly correlated and reduced in patients with ADC and opportunistic infections compared to the other groups. The opportunistic infection group but not the ADC patients had lower CSF Aβ(1-42 )in comparison to the other HIV+ subjects. CSF t-tau levels were high in some ADC patients, but did not differ significantly from the HIV+ neuroasymptomatic group, while CSF p-tau was not increased in any of the HIV+ groups. Together, CSF amyloid and tau markers segregated the ADC patients from both HIV+ and HIV- neuroasymptomatics and from Alzheimer's disease patients, but not from those with opportunistic infections. CONCLUSIONS: Parallel reductions of CSF sAPPα and sAPPβ in ADC and CNS opportunistic infections suggest an effect of CNS immune activation or inflammation on neuronal amyloid synthesis or processing. Elevation of CSF t-tau in some ADC and CNS infection patients without concomitant increase in p-tau indicates neural injury without preferential accumulation of hyperphosphorylated tau as found in Alzheimer's disease. These biomarker changes define pathogenetic pathways to brain injury in ADC that differ from those of Alzheimer's disease. BioMed Central 2009-12-22 /pmc/articles/PMC2807422/ /pubmed/20028512 http://dx.doi.org/10.1186/1471-2377-9-63 Text en Copyright ©2009 Gisslén et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Gisslén, Magnus
Krut, Jan
Andreasson, Ulf
Blennow, Kaj
Cinque, Paola
Brew, Bruce J
Spudich, Serena
Hagberg, Lars
Rosengren, Lars
Price, Richard W
Zetterberg, Henrik
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title_full Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title_fullStr Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title_full_unstemmed Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title_short Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
title_sort amyloid and tau cerebrospinal fluid biomarkers in hiv infection
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807422/
https://www.ncbi.nlm.nih.gov/pubmed/20028512
http://dx.doi.org/10.1186/1471-2377-9-63
work_keys_str_mv AT gisslenmagnus amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT krutjan amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT andreassonulf amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT blennowkaj amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT cinquepaola amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT brewbrucej amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT spudichserena amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT hagberglars amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT rosengrenlars amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT pricerichardw amyloidandtaucerebrospinalfluidbiomarkersinhivinfection
AT zetterberghenrik amyloidandtaucerebrospinalfluidbiomarkersinhivinfection